Fusion Pharmaceuticals Scores $2 Billion AstraZeneca Takeover; Biotech Stock Nearly Doubles
AstraZeneca (AZN) said Tuesday is would acquire its longtime partner, Fusion Pharmaceuticals (FUSN), for $2 billion upfront. The biotech stock nearly doubled, hitting a record high. X The deal adds more fire to the radiopharmaceuticals space, analysts said. Fusion is developing next-generation radioconjugates. These medicines deliver a radioactive isotope directly to cancer cells with the … Read more